Advanced search
Publication Cover
Future Science OA Volume 7, 2021 - Issue 4
Submit an article Journal homepage
1,050
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Idarucizumab (Praxbind®) for Dabigatran Reversal in Patients Undergoing Heart Transplantation: a Cohort of Ten Patients

Eran Kalmanovich1 Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France
,
Pascal Battistella1 Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France
,
Philippe Rouviere2 Department of Cardiovascular Surgery, Montpellier University HospitalFrance
,
Bernard Albat2 Department of Cardiovascular Surgery, Montpellier University HospitalFrance
,
Jean-Marc Frapier2 Department of Cardiovascular Surgery, Montpellier University HospitalFrance
,
Roland Demaria2 Department of Cardiovascular Surgery, Montpellier University HospitalFrance
,
Fabien Huet1 Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, FranceORCID Iconhttps://orcid.org/0000-0002-7670-0455
ORCID Icon,
Audrey Agullo1 Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France;2 Department of Cardiovascular Surgery, Montpellier University HospitalFrance
,
Marc Mourad3 Department of Anesthesiology & Critical Care Medicine, Arnaud de Villeneuve Hospital, MontpellierFrance
,
Pascal Colson3 Department of Anesthesiology & Critical Care Medicine, Arnaud de Villeneuve Hospital, MontpellierFrance
,
Florence Leclercq1 Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France
,
Philippe Gaudard3 Department of Anesthesiology & Critical Care Medicine, Arnaud de Villeneuve Hospital, MontpellierFrance
&
François Roubille1 Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, 34295, France;4 PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de MontpellierFranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5288-9687
ORCID Icon show all
Article: FSO689 | Received 30 Oct 2020, Accepted 05 Jan 2021, Published online: 15 Feb 2021

References

  • PonikowskiP , VoorsAA , AnkerSDet al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail.18(8), 891–975 (2016).
  • AnterE , JessupM , CallansDJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation119(18), 2516–2525 (2009).
  • SteffelJ , VerhammeP , PotparaTSet al.The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J.39(16), 1330–1393 (2018).
  • KirchhofP , BenussiS , KotechaDet al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Rev. Esp. Cardiol. (Engl. Ed.)70(1), 50 (2017).
  • KedzioraA , WierzbickiK , MazurPet al.Impact of postoperative bleeding on short-term outcome in patients after orthotopic heart transplantation: a retrospective cohort study. Ann. Transplant21, 689–694 (2016).
  • SchieleF , van RynJ , CanadaKet al.A specific antidote for dabigatran: functional and structural characterization. Blood121(18), 3554–3562 (2013).
  • AlbaladejoP , PernodG , GodierAet al.Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on perioperative haemostasis (GIHP) - September 2016. Anaesth. Crit. Care Pain Med.37(4), 391–399 (2018).
  • KalmanovichE , GaudardP , RoubilleF. Letter on ‘idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation’. Eur. J. Heart Fail.21(6), 818 (2019).
  • EmmersonG. Research Your Therapy - Analyze your Results - and Publish: Examples in JASP, a Free and User Friendly Analysis ToolOld Golden Point Press, Blackwood, Victoria, Australia (2017).
  • van RynJ , StangierJ , HaertterSet al.Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost.103(6), 1116–1127 (2010).
  • PollackCVJr , ReillyPA , EikelboomJet al.Idarucizumab for dabigatran reversal. N. Engl. J. Med.373(6), 511–520 (2015).
  • PollackCVJr , ReillyPA , van RynJet al.Idarucizumab for dabigatran reversal - full cohort analysis. N. Engl. J. Med.377(5), 431–441 (2017).
  • OkuboK , KuwaharaT , TakagiKet al.Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. Am. J. Cardiol.115(12), 1696–1699 (2015).
  • HealeyJS , EikelboomJ , DouketisJet al.Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation126(3), 343–348 (2012).
  • HassanK , BayerN , SchlingloffFet al.Bleeding complications after use of novel oral anticoagulants in patients undergoing cardiac surgery. Ann. Thorac. Surg.105(3), 702–708 (2018).
  • SalernoDM , TsapepasD , PapachristosAet al.Direct oral anticoagulant considerations in solid organ transplantation: a review. Clin. Transplant.31(1), (2017). doi:10.1111/ctr.12873
  • GlundS , StangierJ , SchmohlMet al.Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind Phase I trial. Lancet386(9994), 680–690 (2015).
  • LevyJH , van RynJ , SellkeFWet al.Dabigatran reversal with idarucizumab in patients requiring urgent surgery: a subanalysis of the RE-VERSE AD study.Ann. Surg. (2019).
  • SorianoJR , BonetLA. Idarucizumab in high-risk thoracic surgery. IJOTM9(2), (2018).
  • RimsansJ , RhotenM , SylvesterK , SinghSK , ConnorsJM. Idarucizumab for urgent reversal of dabigatran for heart transplant: a case report. Am. J. Hematol.92(3), E34–e35 (2017).
  • TralhaoA , AguiarC , FerreiraJet al.Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. Thromb. J.15, 23 (2017).
  • Van KeerJM , VanasscheT , DroogneWet al.Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. Eur. J. Heart Fail.21(1), 129–131 (2019).
  • ErdoesG , MartinezLopez De Arroyabe B , BolligerDet al.International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery.. Anaesthesia73(12), 1535–1545 (2018).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.